Christina R Phares1, Kashmira Date2, Philippe Travers3, Carole Déglise4, Nuttapong Wongjindanon5, Luis Ortega6, Ponchanok Rattanadilok Na Bhuket7. 1. Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop E03, Atlanta, GA 30329, USA; Thailand Ministry of Public Health, U.S. Centers for Disease Control and Prevention Collaboration, Ministry of Public Health, Tivanond Road, Nonthaburi 11000, Thailand. Electronic address: cphares@cdc.gov. 2. Global Immunization Division, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop A04, Atlanta, GA 30329, USA. Electronic address: kdate@cdc.gov. 3. Première Urgence-Aide Médicale Internationale, 21/22-26 Mae Sot-Mae Tao road Tak 63110, Thailand. Electronic address: travers_philippe@yahoo.fr. 4. Première Urgence-Aide Médicale Internationale, Paris, France. Electronic address: cdeglise@pu-ami.org. 5. Thailand Ministry of Public Health, U.S. Centers for Disease Control and Prevention Collaboration, Ministry of Public Health, Tivanond Road, Nonthaburi 11000, Thailand. Electronic address: nwongjindanon@cdc.gov. 6. Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop E03, Atlanta, GA 30329, USA; Thailand Ministry of Public Health, U.S. Centers for Disease Control and Prevention Collaboration, Ministry of Public Health, Tivanond Road, Nonthaburi 11000, Thailand. Electronic address: ortegal@cdc.gov. 7. Department of Disease Control, Thailand Ministry of Public Health, Tivanond Road, Nonthaburi 11000, Thailand. Electronic address: tapanokr@yahoo.com.
Abstract
BACKGROUND: During 2005-2012, surveillance in Maela refugee camp, Thailand, identified four cholera outbreaks, with rates up to 10.7 cases per 1000 refugees. In 2013, the Thailand Ministry of Public Health sponsored a two-dose oral cholera vaccine (OCV) campaign for the approximately 46,000 refugees living in Maela. METHODS: We enumerated the target population (refugees living in Maela who are ≥1 year old and not pregnant) in a census three months before the campaign and issued barcoded OCV cards to each individual. We conducted the campaign using a fixed-post strategy during two eight-day rounds plus one two-day round for persons who had missed their second dose and recorded vaccine status for each individual. To identify factors associated with no vaccination (versus at least one dose) and those associated with adverse events following immunization (AEFI), we used separate marginal log-binomial regression models with robust variance estimates to account for household clustering. RESULTS: A total of 63,057 OCV doses were administered to a target population of 43,485 refugees. An estimated 35,399 (81%) refugees received at least one dose and 27,658 (64%) received two doses. A total of 993 additional doses (1.5%) were wasted including 297 that were spat out. Only 0.05% of refugees, mostly children, could not be vaccinated due to repeated spitting. Characteristics associated with no vaccination (versus at least one dose) included age ≥15 years (versus 1-14 years), Karen ethnicity (versus any other ethnicity) and, only among adults 15-64 years old, male sex. Passive surveillance identified 84 refugees who experienced 108 AEFI including three serious but coincidental events. The most frequent AEFI were nausea (49%), dizziness (38%), and fever (30%). Overall, AEFI were more prevalent among young children and older adults. CONCLUSIONS: Our results suggest that mass vaccination in refugee camps with a two-dose OCV is readily achievable and AEFI are few. Published by Elsevier Ltd.
BACKGROUND: During 2005-2012, surveillance in Maela refugee camp, Thailand, identified four cholera outbreaks, with rates up to 10.7 cases per 1000 refugees. In 2013, the Thailand Ministry of Public Health sponsored a two-dose oral cholera vaccine (OCV) campaign for the approximately 46,000 refugees living in Maela. METHODS: We enumerated the target population (refugees living in Maela who are ≥1 year old and not pregnant) in a census three months before the campaign and issued barcoded OCV cards to each individual. We conducted the campaign using a fixed-post strategy during two eight-day rounds plus one two-day round for persons who had missed their second dose and recorded vaccine status for each individual. To identify factors associated with no vaccination (versus at least one dose) and those associated with adverse events following immunization (AEFI), we used separate marginal log-binomial regression models with robust variance estimates to account for household clustering. RESULTS: A total of 63,057 OCV doses were administered to a target population of 43,485 refugees. An estimated 35,399 (81%) refugees received at least one dose and 27,658 (64%) received two doses. A total of 993 additional doses (1.5%) were wasted including 297 that were spat out. Only 0.05% of refugees, mostly children, could not be vaccinated due to repeated spitting. Characteristics associated with no vaccination (versus at least one dose) included age ≥15 years (versus 1-14 years), Karen ethnicity (versus any other ethnicity) and, only among adults 15-64 years old, male sex. Passive surveillance identified 84 refugees who experienced 108 AEFI including three serious but coincidental events. The most frequent AEFI were nausea (49%), dizziness (38%), and fever (30%). Overall, AEFI were more prevalent among young children and older adults. CONCLUSIONS: Our results suggest that mass vaccination in refugee camps with a two-dose OCV is readily achievable and AEFI are few. Published by Elsevier Ltd.
Authors: Elizabeth C Lee; Michael R Kelly; Brad M Ochocki; Segun M Akinwumi; Karen E S Hamre; Joseph H Tien; Marisa C Eisenberg Journal: J Theor Biol Date: 2017-01-24 Impact factor: 2.691
Authors: Heather M Scobie; Christina R Phares; Kathleen A Wannemuehler; Edith Nyangoma; Eboni M Taylor; Anna Fulton; Nuttapong Wongjindanon; Naw Rody Aung; Phillipe Travers; Kashmira Date Journal: PLoS Negl Trop Dis Date: 2016-12-19
Authors: Marc Poncin; Gideon Zulu; Caroline Voute; Eva Ferreras; Clara Mbwili Muleya; Kennedy Malama; Lorenzo Pezzoli; Jacob Mufunda; Hugues Robert; Florent Uzzeni; Francisco J Luquero; Elizabeth Chizema; Iza Ciglenecki Journal: Bull World Health Organ Date: 2017-10-19 Impact factor: 9.408
Authors: Amber Hsiao; Sachin N Desai; Vittal Mogasale; Jean-Louis Excler; Laura Digilio Journal: Bull World Health Organ Date: 2017-02-21 Impact factor: 9.408
Authors: Elise M O'Connell; Tarissa Mitchell; Marina Papaiakovou; Nils Pilotte; Deborah Lee; Michelle Weinberg; Potsawin Sakulrak; Dilok Tongsukh; Georgiette Oduro-Boateng; Sarah Harrison; Steven A Williams; William M Stauffer; Thomas B Nutman Journal: Emerg Infect Dis Date: 2018-08 Impact factor: 6.883
Authors: Jenny A Walldorf; Kashmira A Date; Nandini Sreenivasan; Jennifer B Harris; Terri B Hyde Journal: Emerg Infect Dis Date: 2017-12 Impact factor: 6.883